Related Experiment Video
Updated: May 9, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia
Naval Daver1, Aditi Shastri, Tapan Kadia
1Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
We evaluated single agent pomalidomide for myelofibrosis-associated anemia. First, 21 patients received pomalidomide 3.0mg/day on 21-day-on/7-day-off schedule. Due to poor tolerance the study was quickly suspended. Second, 29 patients received pomalidomide 0.5mg/day continuously. Three patients (10%) experienced clinical improvement in hemoglobin per International-Working-Group criteria (median time to response 1.6 months; median response duration 6.7 months). Ten patients were RBC-transfusion-dependent per Delphi criteria; 2 (20%) achieved RBC-transfusion-independence (time to response 0.9 months in both; response duration of 8.3 and 15 months). One grade 3/4 toxicity (neutropenia) occurred. Pomalidomide at low dose is well tolerated but has modest clinical activity in myelofibrosis.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Differentiation of Common Myeloid Progenitor Cells
Hematopoiesis
Multipotency of Hematopoietic Stem Cells
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Regulation of Hematopoietic Stem Cells
